Skip to main content
Sign In

David Ross Camidge, MD, PhD

Associate Professor, Division of Medical Oncology

 Camidge Photo

Education: MD, PhD

MRC Laboratory of Molecular Biology
Cambridge University, Cambridge, UK - 1992
Oxford University Medical School, Oxford, UK – 1995

Dr. Camidge joined the University of Colorado as a visiting professor in November of 2005, and was recruited as full-time faculty in October of 2007.

He is the Director of the Thoracic Oncology Clinical Program and the Program Director for the Thoracic Oncology Clinical and Translational Research Fellowship - a unique training program that provides extended research exposure for U.S. or International Senior Fellows interested in Thoracic Oncology. His focus is in Thoracic Malignancies and Developmental Therapeutics (Phase I studies). In 2012 he was announced as the recipient of the 5th Bonnie J. Addario Lectureship as a ‘Luminary in the quest to eradicate lung cancer.’ In 2013 he became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being ‘one of the leading minds in lung cancer today.’

Dr. Camidge is dual-trained in medical oncology and clinical pharmacology. The Developmental Therapeutics Program acquires access to a broad range of new drugs and in conjunction with the comprehensive Thoracic Oncology Program - including a multi-disciplinary thoracic tumor board, exceptional translational science collaborators and the busy thoracic medical oncology cancer clinics - provides outstanding opportunities to develop new drugs for treating patients with thoracic malignancies. Dr. Camidge is the principal investigator on numerous national and international therapeutic trials.

  • IASLC Young investigator Award and University of Colorado Lung Cancer SPORE Pilot Project Award:  Mechanisms of cell death in non-small-cell lung cancer.
  • NIH R21:  Phase I dose-escalation/randomized Phase II cross-over study of anti-IGF-1R monoclonocal antibody IMC-A12 in patients with advanced non-small cell lung cancer.
  • Bonnie J. Addario Lung Cancer Foundation: Comparison of ALK detection methodologies; Detecting RET gene rearrangements in NSCLC.
  • South West Oncology Group: SWOG1300 - A randomized, phase II trial of crizotinib plus pemetrexed versus pemetrexed alone in ALK-positive non-squamous NSCLC patients who have progressed systemically after previous clinical benefit from crizotinib monotherapy (pending).
In addition, Dr. Camidge has written and is/has been the Principal Investigator on a number of Investigator Initiated Clinical Trials in the Thoracic Malignancies and Developmental Therapeutics programs, either taken on and run by the pharmaceutical industry directly including from Boehringer Ingeleheim (High Dose Intermittent (HDI) afatinib), or run through UCCC funded by industry-related grants including from Bayer/Onyx and Merck (sorafenib in combination with vorinostat); and Ariad (ponatinib).

Selected Publications

Weickhardt AJ, Rothman MS, Salian-Mehta S, Kiseljak-Vassiliades K, Oton AB, Doebele RC, Wierman ME, Camidge DR. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 2012 Apr 4. doi: 10.1002/cncr.27450. [Epub ahead of print]

Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Investigational New Drugs 2012 Mar 14. [Epub ahead of print]

Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. British Journal of Cancer 2012 Feb 28. doi: 10.1038/bjc.2012.60. [Epub ahead of print]

Doebele RC, Conkling P, Traynor AM, Otterson GA, Zhao Y, Wind S, Stopfer P, Kaiser R, Camidge DR. A phase I, open-label, dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. Annals of Oncology 2012; doi: 10.1093/annonc/mdr

West HJ, Camidge DR. Have mutation, will travel: utilizing online patient communities and new trial strategies to optimize clinical research in the era of molecularly diverse oncology. J Thorac Oncol. 2012 Mar;7(3):482-4.

Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, Doebele RC, Barón AE, Varella-Garcia M. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer. 2012 Jan 26. doi: 10.1002/cncr.27411. [Epub ahead of print]

Camidge DR. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 2012 Jan 26. doi: 10.1002/cncr.27409. [Epub ahead of print]

Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2012 Jan 10. [Epub ahead of print]

Doebele RC, Pilling AB, Aisner D, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer. Clinical Cancer Research 2012 Jan 10. [Epub ahead of print] 

Chow LQ, Blais N, Jonker DJ, Laurie SA, Diab SG, Canil C, McWilliam M, Thall A, Ruiz-Garcia A, Zhang K, Tye L, Chao RC, Camidge DR. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemother Pharmacol. 2011 Oct 12. [Epub ahead of print]

Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncology 2011 Sep 16. [Epub ahead of print]

Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA Jr, Camidge DR. A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2011; 29(26):3567-35 73.

Camidge DR, Kono SA, Lu X, Okuyama S, Baron AE, Oton AB, Davies AM, Varella-Garcia M, Franklin WA, Doebele RC. Anaplastic Lymphoma Kinase (ALK) gene rearrangements in non-small cell lung cancer are associated with prolonged progression free survival on pemetrexed. Journal of Thoracic Oncology 2011; 6(4):774-780

Camidge DR, Kono SA, Flacco A, Tan A-C, Doebele RC, Zhou Q, Crino L, Franklin WA, Varella-Garcia M. Optimizing the detection of lung cancer patients harboring Anaplastic Lymphoma Kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clinical Cancer Research 2010; 16(22):5581-5590

Kwak L, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New England Journal of Medicine 2010; 363:1693-1703

PubMed Articles


© The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.